相关实验视频
Updated: Jun 4, 2025

06:21
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
28
使用生物信息学揭示中医治疗性结肠炎的治疗和药物
Feng Xu1, Xiaofen Li1, Xiangpei Wang2
1Department of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Journal of biomolecular structure & dynamics
|December 18, 2024
概括
这项研究使用生物信息学识别了中药治疗性结肠炎 (UC) 的37个关键治疗标和33种安全化合物. 这些发现为UC患者提供了潜在的新疗法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
背景情况:
- 性结肠炎 (UC) 的发病和治疗仍然是具有挑战性的研究领域.
- 中国医学为新的UC治疗点和药物提供了潜在的来源.
研究的目的:
- 通过对中国医学的生物信息学分析,选治疗标和UC药物.
- 确定与UC免疫细胞透相关的诊断生物标志物和核心标.
- 为了验证来自中国医学的潜在UC治疗化合物.
主要方法:
- 下载并分析了五个GEO数据集,使用三个机器学习算法来识别UC诊断生物标志物.
- 收集了与新陈代谢,细胞死亡,信号和器官功能相关的基因组,以选核心目标.
- 分析了治疗基因与免疫细胞透之间的关联.
- 通过分子对接,模拟和文献审查对UC目标进行选的中医药化合物.
主要成果:
- 确定了37个UC的关键治疗点,包括5个诊断生物标志物 (CCL11,CXCL1,PDZK1IP1,TIMP1,UGT2A3) 和32个核心点.
- 发现UC治疗点和免疫细胞透,特别是中性细胞,巨细胞,巨细胞和树突细胞之间存在强烈的关联.
- 通过分子对接,模拟和文献数据,确定了33种来自中国医学的安全化合物,这些化合物有可能减轻UC的危害.
结论:
- 这项研究提供了潜在的治疗点和中医药衍生药物治疗性结肠炎.
- 已确定的标和化合物需要进一步实验验证,以获得临床应用.
- 生物信息学方法可以有效地揭示UC等复杂疾病的新疗法策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
315
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
315
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Inflammatory Bowel Disease I: Ulcerative Colitis
135
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
135

